Shire plc (LSE:SHP; NASDAQ:SHPG) has done at least 12 early stage and discovery deals in the Orphan and rare disease space since 2008. The range of deal structures gives the specialty biopharmaceutical company multiple shots on goal without tying its hands to any one platform technology. Most recent deal at top. Source: BCIQ: BioCentury Online Intelligence; company press releases; and SEC filings

Company

Type

Deal

Financials

Date

Nimbus Discovery LLC

Partnership

Use Nimbus' computational drug discovery technologies to profile molecules against undisclosed targets to treat lysosomal storage disorders; Shire has an option to acquire the program after preclinical testing

Shire will fund the three-year deal; Nimbus is eligible for undisclosed milestones

May-13

ethris GmbH

Partnership

Develop and commercialize RNA-based therapies for protein replacement based on ethris' stable and non-immunogenic messenger RNA (SNIM-RNA)

Undisclosed

Jan-13

Sangamo BioSciences Inc. (NASDAQ:SGMO)

Partnership

Use Sangamo's zinc finger DNA-binding protein (ZFP) technology to develop therapeutics for hemophilia A and B and other monogenic diseases

$13M up front plus up to $213.5M in milestones; royalties; Shire will reimburse Sangamo for research costs

Feb-12